Crispr On Hold While Sangamo Accelerates – Seeking Alpha
hcanews.com |
Crispr On Hold While Sangamo Accelerates
Seeking Alpha The gene editing group relying on Crispr was negatively impacted by the FDA hold on CTX001 last week. The regulatory pathway for gene therapy approval is being revised with a notable focus on RMAT, manufacturing and platforms. Sangamo receives CTA … Sangamo Gets Green Light for UK Clinical Trials |
